Pricing Log in Create free account

Lyell Immunopharma, Inc. (LYEL) vs Zura Bio Limited (ZURA)

Lyell Immunopharma, Inc. and Zura Bio Limited are both Biotechnology companies. Lyell Immunopharma, Inc. and Zura Bio Limited are of similar size ($367.6M and $358.3M). Zura Bio Limited has the higher net margin (0.00% vs −1,701,066.7%) and the higher return on invested capital (0.00% vs −1,070.8%). Across the 12 metrics below, Zura Bio Limited leads on 9 and Lyell Immunopharma, Inc. on 3.

Valuation

Metric LYEL ZURA Biotechnology median
P/E n/m n/m 10.60
P/S 24,142.77 n/m 9.40
P/B 1.88 2.95 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 12,335.70 n/m 9.02
Earnings yield (84.75%) (27.30%) (32.88%)
Free cash flow yield (49.94%) (16.52%) (23.13%)

Profitability

Metric LYEL ZURA Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin (1,783,580.00%) 0.00% 0.00%
Net margin (1,701,066.67%) 0.00% 0.00%
Free cash flow margin (928,333.33%) 0.00% 0.00%
Return on equity (97.79%) (85.05%) (51.96%)
Return on assets (74.85%) (72.21%) (46.06%)
Return on invested capital (1,070.83%) 0.00% 0.00%

Growth

Metric LYEL ZURA Biotechnology median
Revenue growth (TTM) (63.41%) — 6.76%
EPS growth (last fiscal year) 38.70% (76.67%) 29.88%
Revenue growth, 5-year CAGR (65.85%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LYEL ZURA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.02 11.29 4.97
Net debt to EBITDA 0.94 1.45 1.01

Dividend

Metric LYEL ZURA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LYEL ZURA Biotechnology median
Market cap 367.57m 358.33m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack